Xin Dong, Wei Deng, Leilei Jiang, Dan Yang, Huiming Yu, Dongming Li, Anhui Shi, Rong Yu, Weihu Wang
{"title":"聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)在食管鳞癌患者同步放化疗期间预防中性粒细胞减少的回顾性研究","authors":"Xin Dong, Wei Deng, Leilei Jiang, Dan Yang, Huiming Yu, Dongming Li, Anhui Shi, Rong Yu, Weihu Wang","doi":"10.1016/j.radmp.2022.04.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization rate in patients with esophageal squamous carcinoma during definitive concurrent chemoradiotherapy.</p></div><div><h3>Methods</h3><p>A total of 70 patients with esophageal squamous carcinoma in Peking University Cancer Hospital from January 2019 to December 2020, who received PEG-rhG-CSF during concurrent chemoradiotherapy, were enrolled in this retrospective analysis. There were 32 patients in the preventive group, and 38 patients in the delayed group. The incidence of neutropenia, completion rate of concurrent chemoradiotherapy and neutropenia-related hospitalization rate were compared between PEG-rhG-CSF preventive group and delayed group.</p></div><div><h3>Results</h3><p>The incidence of severe neutropenia (Grades 3–4) in all patients was 31.4%. Comparison between preventive group and delayed group showed that the incidence of severe neutropenia was 6.3% and 39.4% (χ<sup>2</sup> = 10.428, <em>P</em> = 0.001), respectively. In preventive group, the incidence of severe neutropenia was 3.7% and 20.0%, respectively, for primary prevention and secondary prevention of PEG-rhG-CSF (χ<sup>2</sup> = 12.321, <em>P</em> = 0.001). The completion rate of concurrent chemoradiotherapy was 93.8% in the preventive group and 63.2% in the delayed group (χ<sup>2</sup> = 9.220, <em>P</em> = 0.002). The incidence of treatment interruption was 25.7% in the whole group, 12.5% in the preventive group and 36.8% in the delayed group (χ<sup>2</sup> = 5.389, <em>P</em> = 0.020). Seven patients (7/70, 10.0%) were hospitalized and treated with intravenous antibiotics for neutropenia, including 1 in the preventive group and 6 in the delayed group (<em>P</em> = 0.078).</p></div><div><h3>Conclusions</h3><p>Prophylactic use of PEG-rhG-CSF during concurrent chemoradiotherapy for patients with esophageal squamous carcinoma can effectively reduce the incidence of neutropenia, ensure the safety of treatment, and improve the completion rate of concurrent chemoradiotherapy.</p></div>","PeriodicalId":34051,"journal":{"name":"Radiation Medicine and Protection","volume":"3 2","pages":"Pages 81-85"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666555722000223/pdfft?md5=ccac9fa2d2e6fd1826dca57d3f260462&pid=1-s2.0-S2666555722000223-main.pdf","citationCount":"0","resultStr":"{\"title\":\"A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma\",\"authors\":\"Xin Dong, Wei Deng, Leilei Jiang, Dan Yang, Huiming Yu, Dongming Li, Anhui Shi, Rong Yu, Weihu Wang\",\"doi\":\"10.1016/j.radmp.2022.04.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization rate in patients with esophageal squamous carcinoma during definitive concurrent chemoradiotherapy.</p></div><div><h3>Methods</h3><p>A total of 70 patients with esophageal squamous carcinoma in Peking University Cancer Hospital from January 2019 to December 2020, who received PEG-rhG-CSF during concurrent chemoradiotherapy, were enrolled in this retrospective analysis. There were 32 patients in the preventive group, and 38 patients in the delayed group. The incidence of neutropenia, completion rate of concurrent chemoradiotherapy and neutropenia-related hospitalization rate were compared between PEG-rhG-CSF preventive group and delayed group.</p></div><div><h3>Results</h3><p>The incidence of severe neutropenia (Grades 3–4) in all patients was 31.4%. Comparison between preventive group and delayed group showed that the incidence of severe neutropenia was 6.3% and 39.4% (χ<sup>2</sup> = 10.428, <em>P</em> = 0.001), respectively. In preventive group, the incidence of severe neutropenia was 3.7% and 20.0%, respectively, for primary prevention and secondary prevention of PEG-rhG-CSF (χ<sup>2</sup> = 12.321, <em>P</em> = 0.001). The completion rate of concurrent chemoradiotherapy was 93.8% in the preventive group and 63.2% in the delayed group (χ<sup>2</sup> = 9.220, <em>P</em> = 0.002). The incidence of treatment interruption was 25.7% in the whole group, 12.5% in the preventive group and 36.8% in the delayed group (χ<sup>2</sup> = 5.389, <em>P</em> = 0.020). Seven patients (7/70, 10.0%) were hospitalized and treated with intravenous antibiotics for neutropenia, including 1 in the preventive group and 6 in the delayed group (<em>P</em> = 0.078).</p></div><div><h3>Conclusions</h3><p>Prophylactic use of PEG-rhG-CSF during concurrent chemoradiotherapy for patients with esophageal squamous carcinoma can effectively reduce the incidence of neutropenia, ensure the safety of treatment, and improve the completion rate of concurrent chemoradiotherapy.</p></div>\",\"PeriodicalId\":34051,\"journal\":{\"name\":\"Radiation Medicine and Protection\",\"volume\":\"3 2\",\"pages\":\"Pages 81-85\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666555722000223/pdfft?md5=ccac9fa2d2e6fd1826dca57d3f260462&pid=1-s2.0-S2666555722000223-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiation Medicine and Protection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666555722000223\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Health Professions\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Medicine and Protection","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666555722000223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0
摘要
目的比较聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)预防或延迟治疗中性粒细胞减少症的疗效和安全性、同步放化疗完成率和食管癌患者同步放化疗的住院率。方法回顾性分析2019年1月至2020年12月北京大学肿瘤医院同步放化疗期间接受PEG-rhG-CSF治疗的食管鳞癌患者70例。预防组32例，延迟组38例。比较PEG-rhG-CSF预防组与延迟组中性粒细胞减少发生率、同步放化疗完成率及中性粒细胞减少相关住院率。结果所有患者重度中性粒细胞减少症(3-4级)发生率为31.4%。预防组和延迟组的严重中性粒细胞减少发生率分别为6.3%和39.4% (χ2 = 10.428, P = 0.001)。预防组PEG-rhG-CSF一级预防和二级预防的严重中性粒细胞减少发生率分别为3.7%和20.0% (χ2 = 12.321, P = 0.001)。预防组同期放化疗完成率为93.8%，延迟组为63.2% (χ2 = 9.220, P = 0.002)。治疗中断发生率全组为25.7%，预防组为12.5%，延迟组为36.8% (χ2 = 5.389, P = 0.020)。7例(7/70,10.0%)患者因中性粒细胞减少症住院并静脉应用抗生素治疗，其中预防组1例，延迟组6例(P = 0.078)。结论食管鳞癌患者同步放化疗中预防性使用PEG-rhG-CSF可有效降低中性粒细胞减少的发生率，保证治疗的安全性，提高同步放化疗的完成率。
A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma
Objective
To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization rate in patients with esophageal squamous carcinoma during definitive concurrent chemoradiotherapy.
Methods
A total of 70 patients with esophageal squamous carcinoma in Peking University Cancer Hospital from January 2019 to December 2020, who received PEG-rhG-CSF during concurrent chemoradiotherapy, were enrolled in this retrospective analysis. There were 32 patients in the preventive group, and 38 patients in the delayed group. The incidence of neutropenia, completion rate of concurrent chemoradiotherapy and neutropenia-related hospitalization rate were compared between PEG-rhG-CSF preventive group and delayed group.
Results
The incidence of severe neutropenia (Grades 3–4) in all patients was 31.4%. Comparison between preventive group and delayed group showed that the incidence of severe neutropenia was 6.3% and 39.4% (χ2 = 10.428, P = 0.001), respectively. In preventive group, the incidence of severe neutropenia was 3.7% and 20.0%, respectively, for primary prevention and secondary prevention of PEG-rhG-CSF (χ2 = 12.321, P = 0.001). The completion rate of concurrent chemoradiotherapy was 93.8% in the preventive group and 63.2% in the delayed group (χ2 = 9.220, P = 0.002). The incidence of treatment interruption was 25.7% in the whole group, 12.5% in the preventive group and 36.8% in the delayed group (χ2 = 5.389, P = 0.020). Seven patients (7/70, 10.0%) were hospitalized and treated with intravenous antibiotics for neutropenia, including 1 in the preventive group and 6 in the delayed group (P = 0.078).
Conclusions
Prophylactic use of PEG-rhG-CSF during concurrent chemoradiotherapy for patients with esophageal squamous carcinoma can effectively reduce the incidence of neutropenia, ensure the safety of treatment, and improve the completion rate of concurrent chemoradiotherapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
